The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.

Antzeko izenburuak

• The phosphoinositide-3-kinase inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non small cell lung cancer xenografts.
  nork: Ihle, Nathan T., et al.
  Argitaratua: (2005)
• Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
  nork: Ihle, Nathan T., et al.
  Argitaratua: (2010)
• Take your PIK: PI-3-kinase inhibitors race through the clinic and towards cancer therapy
  nork: Ihle, Nathan T., et al.
  Argitaratua: (2009)
• The PPARγ agonist pioglitazone prevents the hyperglycemia caused by phosphoinositide-3-kinase pathway inhibition by PX-866 without affecting antitumor activity
  nork: Ihle, Nathan T., et al.
  Argitaratua: (2009)
• Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 while oncogenic Ras is a dominant predictor for resistance
  nork: Ihle, NathanT., et al.
  Argitaratua: (2009)